ADVERTISEMENT

Pfizer Q2 Results Review - Subuded Growth, NCE Pipeline Commercialisation Is Awaited: Systematix

The brokerage upgrades its rating from Hold to Buy with a price target of Rs 6,375.

<div class="paragraphs"><p>Exterior of Pfizer Ltd. head office building in BKC, Mumbai. (Photographer: Vijay Sartape Source /NDTV Profit)</p></div>
Exterior of Pfizer Ltd. head office building in BKC, Mumbai. (Photographer: Vijay Sartape Source /NDTV Profit)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More